Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

The Lancet

Volumn 387, Issue 10027, 2016, Pages 1551-1560

  Lonial, Sagar ^a   Weiss, Brendan M ^b   Usmani, Saad Z ^c   Singhal, Seema ^d   Chari, Ajai ^e   Bahlis, Nizar J ^f   Belch, Andrew ^g   Krishnan, Amrita ^h   Vescio, Robert A ⁱ   Mateos, Maria Victoria ^j   Mazumder, Amitabha ^k   Orlowski, Robert Z ^l   Sutherland, Heather J ^m   Bladé, Joan ⁿ   Scott, Emma C ^o   Oriol, Albert ^p   Berdeja, Jesus ^q   Gharibo, Mecide ^r   Stevens, Don A ^s   Leblanc, Richard ^t   Sebag, Michael ^u   Callander, Natalie ^v   Jakubowiak, Andrzej ^w   White, Darrell ^x   De La Rubia, Javier ^y   Richardson, Paul G ^z   Lisby, Steen ^aa   Feng, Huaibao ^ab   Uhlar, Clarissa M ^ab   Khan, Imran ^ab   Ahmadi, Tahamtan ^ab   Voorhees, Peter M ^ac   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g CROSS CANCER INSTITUTE   (Canada)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF TEXAS   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^q SARAH CANNON RESEARCH INSTITUTE   (United States)

^r ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^s Norton Health Care   (United States)

^t MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^u ROYAL VICTORIA HOSPITAL   (Canada)

^v UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^w UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^x DALHOUSIE UNIVERSITY   (Canada)

^y UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^z HARVARD MEDICAL SCHOOL   (United States)

^aa Genmab   (Denmark)

^ab JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^ac UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; METHYLPREDNISOLONE; PARACETAMOL; POMALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; COUGHING; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; INFLUENZA A (H1N1); INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; THROAT IRRITATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CANADA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; SPAIN; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; SPAIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84953325096     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01120-4     Document Type: Article

References (25)

1. C Rollig, S Knop, M Bornhauser Multiple myeloma Lancet 385 2015 2197 2208
2. SK Kumar, SV Rajkumar, A Dispenzieri et al. Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
3. I Turesson, R Velez, SY Kristinsson, O Landgren Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study J Clin Oncol 28 2010 830 834
4. SK Kumar, JH Lee, JJ Lahuerta et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
5. J Kuroda, H Nagoshi, Y Shimura, M Taniwaki Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma Expert Rev Anticancer Ther 13 2013 1081 1088
6. M de Weers, YT Tai, MS van der Veer et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors J Immunol 186 2011 1840 1848
7. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. 56th ASH Annual Meeting and Exposition; San Francisco, CA, USA; Dec 6-9, 2014. Abstract 3474.
8. MB Overdijk, S Verploegen, M Bogels et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma MAbs 7 2015 311 321
9. JHM Jansen, P Boross, MB Overdijk, JJ Lammerts van Bueren, PWHI Parren, HHW Leusen Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking Blood 120 2012 2974 (abstr).
10. HM Lokhorst, T Plesner, JP Laubach et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma N Engl J Med 373 2015 1207 1219
11. BGM Durie, JL Harousseau, JS Miguel et al. International uniform response criteria for multiple myeloma Leukemia 20 2006 1467 1473
12. SV Rajkumar, JL Harousseau, B Durie et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood 117 2011 4691 4695
13. US Department of Health and Human Services National Institutes of Health National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf (accessed Nov 5, 2014).
14. CI Chapuy, RT Nicholson, MD Aguad et al. Resolving the daratumumab interference with blood compatibility testing Transfusion 2015 10.1111/trf.13069 published online March 12
15. WJ Chng, A Dispenzieri, CS Chim et al. IMWG consensus on risk stratification in multiple myeloma Leukemia 28 2014 269 277
16. JA Zonder, AF Mohrbacher, S Singhal et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood 120 2012 552 559
17. S Lonial, M Dimopoulos, A Palumbo et al. Elotuzumab therapy for relapsed or refractory multiple myeloma N Engl J Med 373 2015 621 631
18. JL Harousseau, H vet-Loiseau, M Attal et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials J Clin Oncol 27 2009 5720 5726
19. P Kapoor, SK Kumar, A Dispenzieri et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma J Clin Oncol 31 2013 4529 4535
20. PG Richardson, DS Siegel, R Vij et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study Blood 123 2014 1826 1832
21. DS Siegel, T Martin, M Wang et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825
22. J San Miguel, K Weisel, P Moreau et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 1055 1066
23. T Plesner, HT Arkenau, HM Lokhorst et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma Blood 124 2014 84 (abstr).
24. P Moreau, MV Mateos, J Bladé et al. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma Blood 124 2014 176 (abstr).
25. JP Laubach, PG Richardson CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon Clin Cancer Res 21 2015 2660 2662